Praxis Precision Medicines, Inc. financial data

Symbol
PRAX on Nasdaq
Industry
Pharmaceutical Preparations
Location
99 High Street, 30 Th Floor, Boston, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2024 - May 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 699 % +79.6%
Debt-to-equity 17.7 % -53.6%
Return On Equity -102 % +46.3%
Return On Assets -86.7 % +37.1%
Operating Margin -5.93 K % +78%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 13.2 M shares -78.7%
Common Stock, Shares, Outstanding 13.3 M shares -77.1%
Entity Public Float 147 M USD +42%
Common Stock, Value, Issued 13 K USD +117%
Weighted Average Number of Shares Outstanding, Basic 13.9 M shares +293%
Weighted Average Number of Shares Outstanding, Diluted 13.9 M shares +293%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.2 M USD +221%
Research and Development Expense 88.2 M USD -31%
General and Administrative Expense 44.1 M USD -22.6%
Operating Income (Loss) -130 M USD +29.3%
Nonoperating Income (Expense) 4.79 M USD +228%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -43.9 M USD +1.69%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -125 M USD +31.4%
Earnings Per Share, Basic -11 USD/shares +86.1%
Earnings Per Share, Diluted -11 USD/shares +86.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 152 M USD +88%
Cash, Cash Equivalents, and Short-term Investments 243 M USD
Assets, Current 212 M USD +124%
Property, Plant and Equipment, Net 476 K USD -45%
Operating Lease, Right-of-Use Asset 1.84 M USD -31.9%
Other Assets, Noncurrent 416 K USD 0%
Assets 250 M USD +155%
Accounts Payable, Current 9.4 M USD -44.6%
Accrued Liabilities, Current 6.98 M USD -25.4%
Contract with Customer, Liability, Current 1.26 M USD -50.6%
Liabilities, Current 18.8 M USD -37.2%
Contract with Customer, Liability, Noncurrent 866 K USD -51.2%
Operating Lease, Liability, Noncurrent 1.07 M USD -52.1%
Liabilities 20.7 M USD -38.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 3 K USD
Retained Earnings (Accumulated Deficit) -693 M USD -22.1%
Stockholders' Equity Attributable to Parent 230 M USD +256%
Liabilities and Equity 250 M USD +155%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -20.9 M USD +36.5%
Net Cash Provided by (Used in) Financing Activities 183 M USD +911%
Net Cash Provided by (Used in) Investing Activities -91.2 M USD -368%
Common Stock, Shares Authorized 150 M shares 0%
Common Stock, Shares, Issued 13.3 M shares -77.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 70.7 M USD +268%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 152 M USD +87.6%
Deferred Tax Assets, Valuation Allowance 181 M USD +25.4%
Deferred Tax Assets, Gross 181 M USD +25.2%
Operating Lease, Liability 2.5 M USD -28.7%
Depreciation 112 K USD +5.66%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -125 M USD +31.2%
Lessee, Operating Lease, Liability, to be Paid 2.73 M USD -31.8%
Property, Plant and Equipment, Gross 1.59 M USD +3.24%
Operating Lease, Liability, Current 1.16 M USD +11.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.32 M USD +1.93%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.3 M USD +2.05%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 232 K USD -53.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 110 K USD -91.7%
Deferred Tax Assets, Operating Loss Carryforwards 74.5 M USD +24.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 110 K USD -91.7%
Additional Paid in Capital 923 M USD +45.9%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 559 K USD -24.9%
Share-based Payment Arrangement, Expense 31.7 M USD +12.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%